Armada introduces ReachRx OTM
FLORHAM PARK, N.J. — Armada Health Care has launched a new Web-based specialty pharmacy therapy management system designed to allow pharmacies to optimize drug utilization and clinical outcomes while providing enhanced patient care, Armada said Monday.
The company announced the launch of ReachRx OTM, which includes features such as patient support protocols, side effects management, therapy discontinuation surveys and patient outcomes reporting.
Armada said the system’s reporting capabilities would assist pharmacies to optimize fiscal management, meet payer requirements and access biotech manufacturer programs requiring patient interventions and reporting.
Tradjenta approved as Type 2 diabetes treatment
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for Type 2 diabetes, the agency said Monday.
The FDA announced the approval of Tradjenta (linagliptin), made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.
“This approval provides another treatment option for the millions of Americans with Type 2 diabetes,” FDA Division of Metabolism and Endocrinology Products director Mary Parks said. “It is effective when used alone or when added to existing treatment regimens.”
Watson announces launch of Generess Fe, patient support program
PARSIPPANY, N.J. — Watson Pharmaceuticals has launched a low-dose chewable contraceptive, the company said Monday.
Watson announced the U.S. commercial launch of Generess Fe (norethindrone and ethinyl estradiol chewable tablets, and ferrous fumarate chewable tablets) in the 0.8-mg/25-mcg strength.
As part of the launch, Watson has created the “I am Generess” patient support program, which caps participant cost for the drug at $25 per prescription and donates $5 in the person’s name to one or more women’s charities of the patient’s choosing, including the National Coalition Against Domestic Violence; the Rape, Abuse and Incest National Network; and the Society for Women’s Health Research.